Fulcrum Therapeutics (FULC) EBIT: 2020-2025
Historic EBIT for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$21.9 million.
- Fulcrum Therapeutics' EBIT rose 13.01% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.8 million, marking a year-over-year decrease of 185.02%. This contributed to the annual value of -$21.9 million for FY2024, which is 80.21% up from last year.
- Per Fulcrum Therapeutics' latest filing, its EBIT stood at -$21.9 million for Q3 2025, which was down 7.13% from -$20.4 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year EBIT high stood at $52.5 million for Q2 2024, and its period low was -$34.2 million during Q2 2022.
- Moreover, its 3-year median value for EBIT was -$26.2 million (2023), whereas its average is -$17.5 million.
- As far as peak fluctuations go, Fulcrum Therapeutics' EBIT surged by 292.33% in 2024, and later slumped by 138.87% in 2025.
- Quarterly analysis of 5 years shows Fulcrum Therapeutics' EBIT stood at -$23.6 million in 2021, then decreased by 18.74% to -$28.0 million in 2022, then fell by 0.07% to -$28.0 million in 2023, then spiked by 30.59% to -$19.4 million in 2024, then increased by 13.01% to -$21.9 million in 2025.
- Its EBIT stands at -$21.9 million for Q3 2025, versus -$20.4 million for Q2 2025 and -$19.4 million for Q4 2024.